BioSpace News Archive

Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the second quarter ended June 30, 2020. “We have had a busy second quarter with data updates across our portfolio at key medical and scientific conferences,” said Dr Christian Itin, chairman and chief executive officer of Autolus. “Both our later stage p

Spinoff Would Unlock Value in the Iconic Bausch + Lomb Brand and Integrated Portfolio of Eye Health Products

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the Canaccord Genuity 40 th Annual Growth Conference on Thursday,

Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, announced that the Centers for Medicare and Medicaid Services established a new permanent J-code for ANJESO injection facilitating reimbursement in the hospital outpatient, ambulatory surgery center and physician office settings of care.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40 th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com.

Regulatory and Clinical Progress in MLD, MPS-I and MPS-IIIA Illustrate Execution in Neurometabolic Disorders; EU Regulatory Decision for Libmeldy ™ Expected in 2H 2020 MolMed and GSK Agreements Provide Near-term Manufacturing Capacity and Highlight Future Innovations Near-term Financial Position Secure with Cash and Investments of ~$230M and Runway into 2022 BOSTON and LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, to

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced that it has submitted a request to the U.S. Food and Drug Administration for de novo classification and clearance of the Portable Neuromodulation Stimulator device and reported preliminary financial results for the second quarter and six months ended June 30, 2020.

—ORLADEYO ™ (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021— —200 mg/400mg BCX9930 data from treatment-naïve PNH patients expected in Q3 2020, 200 mg/400mg data from poor-responders to C5 inhibitors expected by year end 2020 — —Information from Part 1 of galidesivir trial in COVID-19 patients expected by end of Q3 2020— RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2020 (GLOBE NE

Factorial Diagnostics and IncellDx announced that they have agreed to terms on an exclusive license and supply agreement for technology that will enable the development of their multi-omic, cancer diagnostic workflow.